Questions around this news
What does the agreement for the Lucid-MS trial cover?
The agreement is a Study Start-Up Agreement between Quantum BioPharma and Thermo Fisher Scientific’s clinical research business. It covers implementation of a phase 2 trial of Lucid-MS, which the release identifies as Quantum’s lead drug candidate for multiple sclerosis. The release describes the agreement as moving the trial from planning toward execution.
How is Lucid-MS’s approach to multiple sclerosis described?
The release says Lucid-MS is designed around a neuroprotective approach that targets demyelination, rather than focusing solely on modulating the immune system. It contrasts this with the immune-system effects of most MS drugs. The release does not provide trial results or further details about how the candidate is intended to work.
What does a phase 2 clinical trial generally assess?
A phase 2 clinical trial generally studies a treatment in people with the condition it is intended to address. It commonly examines whether the treatment shows signs of benefit and gathers information about safety and dosing. The specific design, measures, and goals vary by trial; the release does not provide those details for this study.
What does a contract research organization do in a clinical trial?
A contract research organization provides research-related services to a company or other study sponsor. Depending on the agreement, those services can include planning and coordinating trial activities, managing study sites or data, and helping meet regulatory requirements. The organization’s responsibilities are defined by the particular contract and study.
- New agreement moves innovative Lucid-MS treatment from planning into execution.
- Proprietary platform is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune system.
- Thermo Fisher’s clinical research business is a leading global contract research organization, with impressive expertise in central nervous system and MS studies.
Most multiple sclerosis (“MS”) drugs work by quieting the immune system. A new partnership shines the spotlight on a different approach — protecting the nerve’s own insulation — and sets up that treatment for a rigorous clinical test. Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific. The contract covers implementation of the phase 2 trial of Lucid-MS, Quantum’s lead drug candidate for MS.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Corporate Communications
IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]
Terms explained
- Demyelination
- Damage or loss of myelin, the insulating layer around nerve fibers. It can interfere with the transmission of signals through the nervous system.
- Neuroprotective
- Describes an approach intended to protect nerve cells or their function from damage.
- Contract research organization (CRO)
- An organization that provides research services to companies or other sponsors, including support for planning or conducting clinical trials.
- Central nervous system
- The part of the nervous system made up of the brain and spinal cord.
- Phase 2 trial
- A stage of clinical testing that generally evaluates a treatment in people with the relevant condition, examining potential benefit and gathering safety information.
SEC filings
Earlier from Quantum BioPharma
- Quantum BioPharma (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
- Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing
- Quantum BioPharma (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
- Quantum BioPharma (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves
